Project Grant R43DA059522
Award Date
8/1/24
Completion Date
2/28/25
Dollars Obligated
$221K
Federal Agency
National Institute on Drug Abuse
Federal Grant Program
93.279
Assistance Type
Project Grant
Place of Performance
Greenville, NC 27858, USA
Similar Awards
The National Institute on Drug Abuse (NIDA) awarded a $1,213,117 Project Grant under the Drug Use and Addiction Research Programs (CFDA 93.279) to The Washington University to develop novel compounds that modulate the signaling of the mu opioid receptor (MOR) as potential treatments for pain and opioid use disorder. The research team, in collaboration with scientists at Stanford University and the University of Florida, will synthesize and characterize novel bitopic ligands that target the...
This $362,080 Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to investigate the role of the anterior cingulate cortex (ACC) in regulating spinal cord excitability and associative opioid analgesic tolerance. The primary awardee, Yale University, will use a combination of transgenic tools, fiber photometry, and optogenetics to determine how the ACC integrates context and drug signals to...
This Project Grant award of $1,419,144.00 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the role of OPRM1 exon 7-associated variants in mediating adverse effects of clinically used mu opioids, such as tolerance, reward, and respiratory depression, without impacting analgesia. The key products or services to be delivered under this 5-year award include: Characterizing antisense oligonucleotides (ASOs) and...
This $9,145,390 Cooperative Agreement award from the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports the clinical development of PF614-MPAR, a novel opioid product with abuse-deterrent and overdose protection features. The award will fund studies to evaluate the safety and efficacy of different PF614-MPAR dosage strengths (25 mg, 50 mg, 100 mg) to provide pain relief at prescribed doses while preventing overdose at higher than...
This $708,397 Project Grant awarded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279) supports research on the role of inflammasomes in opioid-induced pain in the context of HIV. The research aims to construct a cell atlas of opioid-targeted inflammasomes in the spinal cord of HIV pain models, elucidate the role of Wnt5a signaling in establishing inflammasome cell maps, and determine the contribution of glial-specific NLRP3 to...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $275,253 to Epivario Inc. to develop a novel epigenetic regulator as a potential treatment for opioid use disorder (OUD). The project aims to screen next-generation compounds that inhibit the metabolic enzyme ACSS2, which plays a key role in drug-related memory and neuroplasticity. Through in vitro and in vivo assays, the company will...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to integrate and assess the practicality of a closed-loop medication management system dispensed through a hospital-based pharmacy to reduce opioid use by discharged emergency department patients. The $295,906 award to Addinex Technologies, Inc. will be used to adapt and enhance the company's ADDINEX system, which utilizes mechanical dispensers with...
This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), is focused on accelerating the development of non-opioid drug candidates to combat the national opioid public health crisis. The $399,536 award to Chemregen Inc. will fund two key activities over the period of March 2025 to February 2026: Design, synthesis, and pharmacological characterization of lead small molecule compounds and control compounds that...
This Project Grant award in the amount of $715,238 was issued on January 15, 2025 by the National Institute on Drug Abuse (NIDA) under the federal Drug Use and Addiction Research Programs (CFDA 93.279). The project will conduct a large-scale genetic study involving a survey of 500,000 diverse individuals to investigate the genetic basis of opioid-related traits and opioid use disorder (OUD). The research aims to elucidate genetic risk factors across the stages of opioid use, from initial use...
This federal Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $772,800 to the University of Florida to conduct research aimed at developing pharmacological tools to selectively manipulate opioid receptor signaling. The overarching goal is to dissociate the beneficial analgesic effects of opioids from their undesirable effects that contribute to dependence and addiction. The researchers plan to use...